IHE: Axolotl tests interoperability with other health IT vendors

Axolotl has announced it successfully passed testing at the Integrating the Healthcare Enterprise (IHE) North American Connectathon event in Chicago.

The company said it successfully demonstrated interoperability with 20 other health IT vendors. Axolotl completed Connectathon testing for the following IHE actors in one or more IHE integration profiles:

• XDS.b Document Registry (Cross-Enterprise Clinical Documents Share profile);
• XDS.b Document Repository (Cross-Enterprise Clinical Documents Share profile);
• PIXv3 Patient Identity Cross-reference Manager (Patient Identifier Cross-Reference HL7 V3 profile); and
• PDQv3 Patient Demographics Supplier (Patient Demographic Query HL7 V3 profile).

These IHE profiles represent the foundation of Axolotl's interoperability services, Axolotl said.

“Axolotl is committed to interoperability solutions that are based on industry standards. Our longstanding involvement with IHE and other standards bodies gives Axolotl industry-leading competencies in developing the standards-based solutions that help solve our customers’ interoperability challenges,” said Glenn Keet, president of Axolotl.

The annual IHE Connectathon promotes the adoption of IHE standards-based interoperability systems in commercially available health IT systems. The Connectathon serves as an industry-wide testing event where participants can test their implementations with those of other vendors. During the Connectathon, systems exchange information with complementary systems from multiple vendors, performing all of the transactions required for the roles they have selected, called IHE Actors, in support of defined clinical use cases, called IHE Profiles.

Around the web

The American College of Cardiology has sent a letter to HHS Secretary Robert F. Kennedy Jr. that outlines some of the organization’s central priorities and concerns. 

One product is being pulled from the market, and the other is receiving updated instructions for use.

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology?